- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
ZS Acquires Digital Health Specialist Medullan to Help Accelerate Innovation for Life Sciences
Acquisition is largest in 37-year history of ZS.
Global professional services firm ZS has announced it is acquiring Medullan, a digital medicine strategies and solutions company.
Medullan has developed specialized resources and tools in the digital medicine space, such as the pioneering virtual care and decentralized trial platform, VARA™.
The acquisition is the largest in the history of ZS, a 37-year-old company that now employs over 8,000 professionals across more than 25 offices worldwide. When the transaction is finalized, Medullan’s 80-plus employees will join ZS’s DCH practice.
“Digital health solutions will transform how we experience healthcare, improve lives and reduce costs in the process. While significant progress has been made, there remain many challenges to overcome toward realizing this vision,” said Pete Masloski, principal at ZS and leader of the DCH practice, which Medullan employees will join.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
